CommercialCoverageMedium impact
Chronic Iron Overload
Blue Cross & Blue Shield of Mississippi·MS · Hematology, Oncology, Pediatrics +1 more·Medical Policy
Effective date
Oct 1, 2024
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their chronic iron overload policy, removing Jadenu (deferasirox) from coverage while maintaining Exjade (deferasirox) coverage. Prior authorization remains required for iron chelation therapy with specific clinical criteria for transfusional iron overload and non-transfusion-dependent thalassemia syndromes.
Action Required
Immediately: Update prior authorization forms and billing systems to remove Jadenu as a covered option for iron chelation therapy. Providers must use Exjade (deferasirox) instead for BCBS Mississippi patients with chronic iron overload. Review current patients on Jadenu and initiate prior authorization requests for alternative coverage or transition to Exjade.